Analyst Price Target is $13.00
▲ +269.32% Upside Potential
This price target is based on 1 analysts offering 12 month price targets for Acurx Pharmaceuticals in the last 3 months. The average price target is $13.00, with a high forecast of $13.00 and a low forecast of $13.00. The average price target represents a 269.32% upside from the last price of $3.52.
Current Consensus is
The current consensus among 1 polled investment analysts is to buy stock in Acurx Pharmaceuticals. This Buy consensus rating has held steady for over two years.
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that has completed Phase IIa clinical trial to treat patients with clostridium difficile infections. It is also developing ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. The company was incorporated in 2017 and is headquartered in Staten Island, New York.